Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, announce that they have entered into a definitive agreement pursuant to which Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for 31.50 USD per share in cash, for a total equity value of approximately 4.1 billion USD (equivalent to 3.5 billion euros) which represents a 21% premium to Catalyst’s unaffected closing share price on April 22, 2026.
Read the full article: Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1B USD, Entering the U.S. Market and Consolidating Its Leadership in Brain Health and Rare Disease //
Source: https://www.globenewswire.com/news-release/2026/05/07/3289616/0/en/angelini-pharma-to-acquire-catalyst-pharmaceuticals-for-4-1-billion-usd-3-5-billion-euros-entering-the-u-s-market-and-consolidating-its-leadership-in-brain-health-and-rare-disease.html?_gl=1*1sk9ir4*_up*MQ..*_ga*MTkyNDkxNjI2MC4xNzc4MTM1Njg1*_ga_B6167QB2TF*czE3NzgxMzU2ODUkbzEkZzAkdDE3NzgxMzU2ODUkajYwJGwwJGgxNzgxNjgwODU.*_ga_ERWPGTJ5X8*czE3NzgxMzU2ODUkbzEkZzAkdDE3NzgxMzU2ODUkajYwJGwwJGgw